$12.6 Billion Valuation! Respiratory Multiplex Nucleic Acid Testing Proves Highly Valuable!

Oct 07, 2024 15:05 CST Updated 15:05

GenMark Diagnostics

Molecular Diagnostics Technology Researcher

Roche

Oncology Drug Research, Development, and Manufacturing

Roche to Acquire GenMark Diagnostics for $24.05 Per Share in All-Cash Transaction, Valuing the Company at Approximately$1.8 billionAfter the acquisition is completed, GenMark's main operations will continue at its existing location in Carlsbad, California, USA. GenMark’s portfolio of syndrome test kits will complement Roche's current molecular diagnostics offerings, while Roche's global network will expand the reach of GenMark’s products.

GenMark’s ePlex system enhances laboratory efficiency through a streamlined order-to-report workflow and improves patient outcomes by rapidly diagnosing patient symptoms. Infectious diseases are a leading cause of death globally, and early detection of the cause of infection has been proven to improve patient outcomes and support critical hospital initiatives such as antibiotic stewardship and length of stay.GenMark's Respiratory Pathogen Panel identifies the most common viral and bacterial microorganisms associated with upper respiratory infections, including SARS-CoV-2, complementing Roche's broad portfolio of COVID-19 diagnostic solutions.

cobas eplex System

GenMark Diagnostics，A Leading Provider of Multiplex Molecular Diagnostic Solutions Aimed at Enhancing Patient Care, Improving Key Quality Metrics, and Reducing Overall Care Costs. GenMark’s eSensor XT-8 and ePlex Systems Utilize GenMark’s Proprietary eSensor Detection Technology, Designed to Support a Wide Range of Molecular Diagnostics from Sample-to-Result through Compact, User-Friendly Workstations and Standalone Disposable Test Cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is Designed to Optimize Laboratory Efficiency and Meet a Broad Range of Infectious Disease Testing Needs, Including Respiratory, Blood, and Gastrointestinal Infections.

April 26, 2024

GenMark, a subsidiary of Roche Group, announced that it has renamed its ePlex systemcobas eplex System。The launch of the cobas eplex system under the globally recognized cobas brand highlights Roche's commitment to continuous product improvement across the entire platform, from raw materials to manufacturing and quality control.

GenMark has renamed its rapid syndrome molecular diagnostic solution to the Roche cobas brand and upgraded its features based on customer feedback in all aspects of the workflow.
The system’s syndrome panel provides rapid, comprehensive diagnostic information for a wide range of pathogens that can cause infections, which cannot be definitively diagnosed from symptoms alone.

Roche and GenMark Diagnostics are committed to providing world-class solutions for multiplex testing, with enhanced capabilities that assist Roche in diagnosing infectious diseases and reducing antibiotic resistance.

"We are excited to offer the redesigned and enhanced cobas eplex system to the healthcare community," said Josh Lauer, Head of Molecular Lab Customer Area at Roche Diagnostics Solutions. "These are syndrome panels, so patients can benefit from rapid, comprehensive diagnosis of a broad range of pathogens that may cause infections with similar symptoms, such as influenza, COVID-19, and RSV. This is particularly important for high-risk patients, including the elderly, the very young, and those who are immunocompromised."

The cobas eplex system is a true sample-to-result solution designed to optimize laboratory efficiency and meet a wide range of infectious disease testing needs, including respiratory, blood, and gastrointestinal infections.

cobas eplex Respiratory Pathogen 2 (RP2) is a multiplex nucleic acid test for the qualitative detection of more than 20 common viral and bacterial pathogens that cause respiratory infections. The Roche RP2 test has not been approved or cleared by the U.S. Food and Drug Administration (FDA). The test has been authorized by the FDA under an Emergency Use Authorization (EUA) for use in authorized laboratories.

cobas eplex Blood Culture Identification Panel (BCID) is a multiplex nucleic acid test for the qualitative detection of ~95% of organisms that can cause bloodstream infections (which can lead to sepsis). This is the broadest coverage of Gram-positive, Gram-negative, and fungal organisms, as well as resistance genes.